Antibodies for neoplastic disease : solid tumors.
The ease with which polyclonal, monoclonal, and engineered antibody fragments can be prepared allows access to a series of reagents with high selectivity and affinity. These reagents therefore have long held promise as a means of influencing the growth and spread of malignant disease. Over a number of decades therapeutic antibodies have been developed either as single entities or conjugated to a variety of potential disease-ameliorating agents.